In response to market manipulation driven by companies in Indonesia, Laos, and India, the petitions were filed by The Alliance for American Solar Manufacturing and Trade.
With President Donald Trump’s recent announcement of 50% tariffs on copper imports under Section 232 of the Trade Expansion Act, the United States has correctly identified copper as a material of strategic national importance.
The Senate’s decision to remove the FEOC Excise Tax and weaken FEOC restrictions is a blatant giveaway to the Chinese Communist Party’s solar industry.
Any Senator who supports an amendment to remove or weaken the FEOC Excise Tax is directly endorsing China’s solar industry—dominated by companies using slave labor, powered by coal, and compromised by severe cybersecurity risks.
CPA strongly endorses the FEOC Excise Tax in the Senate reconciliation bill as a critical step in protecting America’s solar manufacturing industry from reliance on subsidized and compromised Chinese components.
CPA warned that the Senate version of President Trump’s reconciliation bill—known as the One Big Beautiful Bill—contains a critical loophole in both the Section 48E investment tax credit and 45Y production tax credit in the Inflation Reduction Act (IRA), creating an unintended but dangerous giveaway to China’s solar industry.
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
The President’s tariff increase comes at a critical moment, reflecting a clear understanding of the ongoing threats faced by the U.S. aluminum and steel industry, particularly from heavily subsidized foreign competitors.
Yes, reshoring manufacturing is possible. Investors will even go along for the ride, Guardian Bikes CEO Brian Riley told the Senate Small Business Committee in a hearing on May 14.
A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.
